Action steps: The goal of taking a weight loss medication is to become healthier
In this regard, GLP-1 and GIP are therapeutically interesting peptides because they are important mediators of glycaemic homeostasis, as they are responsible for approximately 5070 % of the total insulin secreted after glucose intake (Reference Baggio and Drucker10)
Planning, implementation, and monitoring are interconnected, and decisions made at any stage can influence outcomes later
They'll serve different niches: CagriSema Will Dominate: Patients familiar with Wegovy brand Those wanting proven semaglutide component People with type 2 diabetes (strong REIMAGINE data) Earlier availability (mid-2027) Retatrutide Will Dominate: Patients needing maximum weight loss (BMI 40) Those with multiple complications (OA + OSA + obesity) People who failed CagriSema Willingness to wait for highest efficacy Tirzepatide (Zepbound) Will Remain Relevant: Already available NOW Proven safety with 22.5% weight loss Lower cost than either new option Established insurance coverage The High-Dose CagriSema Wildcard Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026tripling the cagrilintide dose
Outcomes depend on your biology, your training, and your protocol
sermorelin is rarely covered by commercial insurance as a compounded product
